Does menopause-related estrogen decline raise LDL cholesterol and apolipoprotein B?

The transition through menopause is characterized by a profound decline in circulating ovarian hormones, particularly 17β-estradiol. This hormonal shift has direct, adverse consequences on hepatic lipid and lipoprotein metabolism, contributing to a worsening cardiovascular risk profile in postmenopausal women.

Clinical and metabolic evidence

• Elevations in atherogenic particles: Following the menopausal transition, women typically experience a significant increase in circulating low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB). Large-scale longitudinal cohort studies, such as the Study of Women's Health Across the Nation (SWAN; n = 3,000+), demonstrate that the menopausal transition is associated with a 10% to 15% increase in LDL-C and a corresponding rise in ApoB, independent of chronological aging.
• Profound shift in lipoprotein subfractions: The increase in ApoB levels reflects a higher total concentration of atherogenic, ApoB-containing particles (including VLDL and LDL). Postmenopausal women exhibit a redistribution of LDL subfractions toward smaller, denser LDL particles, which are highly susceptible to oxidation and possess an increased atherogenic potential compared to large, buoyant LDL particles.

Mechanistic explanations

• PCSK9 upregulation and LDLR degradation: In premenopausal women, estrogen signaling via hepatic estrogen receptor alpha (ERα) and G-protein coupled estrogen receptor (GPER) exerts a suppressive effect on proprotein convertase subtilisin/kexin type 9 (PCSK9) expression. The postmenopausal drop in estrogen relieves this suppression, leading to increased circulating PCSK9 levels. PCSK9 binds to hepatic low-density lipoprotein receptors (LDLR) on the hepatocyte membrane, routing them to the lysosome for degradation rather than allowing them to recycle to the cell surface.
• Impaired hepatic clearance: Due to the PCSK9-mediated reduction in functional cell-surface LDLR density, the liver's capacity to clear circulating LDL particles from the bloodstream is significantly impaired. This directly prolongs the residence time of LDL particles in circulation, leading to elevated plasma LDL-C.
• Altered VLDL secretion: Estrogen deficiency also impacts transcriptional regulators of lipid metabolism, such as sterol regulatory element-binding protein (SREBP) and liver X receptors (LXR). In the absence of estrogen, hepatic secretion of VLDL (the precursor to LDL, which contains one molecule of ApoB) is enhanced, further compounding the accumulation of circulating atherogenic particles.

Bottom line

• Menopause and the decline in estrogen directly alter hepatic lipoprotein handling by increasing PCSK9 activity and degrading hepatic LDL receptors. This dual mechanism—impaired LDL clearance coupled with altered VLDL secretion—directly drives the elevation of circulating LDL-C and ApoB, increasing cardiovascular risk in postmenopausal women.